While tirzepatide is designed to help control high blood sugar, it could potentially cause low blood sugar, as we mentioned earlier, leading to risks for both the mother and the baby
US20210186943A1 - Otic formulations for drug-induced ototoxicity - Google Patents Otic formulations for drug-induced ototoxicity Download PDF Info Publication number US20210186943A1 US20210186943A1 US17/050,421 US201917050421A US2021186943A1 US 20210186943 A1 US20210186943 A1 US 20210186943A1 US 201917050421 A US201917050421 A US 201917050421A US 2021186943 A1 US2021186943 A1 US 2021186943A1 Authority US United States Prior art keywords formulation otic composition therapeutic agent agent Prior art date Legal status (The legal status is an assumption and is not a legal conclusion
The study found MASLD prevalence to be significantly higher in the IBD group than in the control group (21.3% and 10%, p = 0.022), concluding that IBD is an independent risk factor for MASLD in lean individuals, even after accounting for factors like traditional metabolic risk factors (such as obesity) and prior steroid use [104]
The molecular responses elicited by UA in human plasma and skeletal muscle resemble those induced by conventional exercise training (7), sparking considerable interest in the sports science community
Most IGF molecules are bound by one of the members of the IGF-binding protein (IGFBP) family
Efficient delivery of GLP-1, which can aid in weight management and blood sugar control